Results of a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability & Pharmacodynamics of the Fructokinase Inhibitor PF-06835919 Administered Daily for 16 Weeks in Adults with NAFLD & T2DM
Time: 2:00 pm
day: Day 1 Stream 3 PM
• Revealing results of nonclinical studies and a prior 6-week clinical study in patients with NALFD suggest that the orally administered fructokinase inhibitor PF-06835919 may have the potential to lower liver fat content and improve markers of insulin sensitivity.
• Understanding the steps taken to further assess the potential utility of PF-06835919 for the treatment of NASH and/or insulin resistance, a 16-week randomized, double blind, placebo- controlled study assessing two active doses of PF-06835919 in patients with NAFLD and T2DM was designed and conducted.
• Analyzing our study results in depth